Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CSL Limited | ASX:CSL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.49 | 0.58% | 257.13 | 256.30 | 257.78 | 257.32 | 250.42 | 251.39 | 836,587 | 08:50:00 |
From Apr 2020 to Apr 2025
By Stuart Condie
SYDNEY--Australian biopharmaceutical company CSL Ltd. said it is in talks with Vifor Pharma Ltd. over a potential acquisition of the Switzerland-based pharmaceutical company.
CSL said Monday that there was no certainty of a transaction, or indication of when any transaction would occur. It said it didn't intend to comment further outside of its continuous disclosure obligations.
Vaccine and blood-products maker CSL, the second-largest ASX-listed firm by market capitalization, initially acknowledged Australian media reports on the discussions last week, without confirming their existence.
Investment bank Citi said last week that any move for Vifor would likely be EPS accretive, given CSL trades at a significantly higher multiple than Vifor, which develops, manufactures and markets iron-deficiency products.
Vifor has a market capitalization of 7.69 billion Swiss francs (US$8.35 billion). CSL's market capitalization is A$136 billion (US$97.5 billion).
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
December 12, 2021 19:34 ET (00:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year CSL Chart |
1 Month CSL Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
